Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.80 |
| ▸ | JAK1 | P23458 | 3/20 | 0.62 |
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.62 |
| ▸ | MERTK | Q12866 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379586 | 0.95 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL21412834 | 0.95 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14377767 | 0.95 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14376756 | 0.95 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449882 | 0.93 | JAK2 (0.80) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449884 | 0.93 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22622522 | 0.93 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14377572 | 0.91 | JAK2 (0.82) | JAK2JAK1AXL | |
| SCHEMBL21799144 | 0.91 | JAK2 (0.82) | JAK2JAK1AXL | |
| SCHEMBL14377481 | 0.91 | JAK2 (0.82) | JAK2JAK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030600-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022125670-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021076124-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021072098-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072116-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020191041-A2 | BIOMARKERS FOR VITILIGO | INCYTE CORPORATION (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020132210-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE | INCYTE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019200030-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2017027717-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016183060-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183062-A1 | SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183063-A1 | CRYSTALLINE FORMS OF A PI3K INHIBITOR | INCYTE CORPORATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016138363-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | INCYTE CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2015191677-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015184305-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015131031-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015026818-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |